Summary by Moomoo AI
Kozhi Pharmaceutical Holdings Limited (“Kozhi Pharmaceuticals”) announced on 15 January 2024 that its autologous CAR-T cell candidate product CT011 has received IND approval from the National Drug Administration for the treatment of GPC3-positive stage IIIa liver cell cancer patients at risk of recurrence after surgical excision. CT011 is the first CAR-T cell therapy for solid tumors in China to receive IND approval and has enrolled patients who have completed Phase I clinical trials. Focusing on innovative CAR-T cell therapies to improve treatment safety, efficacy and lower costs, Kozin Pharmaceuticals is committed to becoming a global leader in cancer cell therapy. The Company reminds shareholders and potential investors that the development or sale of CT011 cannot be guaranteed and that caution should be exercised when buying and selling shares.